See more : Carbon Energy Corporation (CRBO) Income Statement Analysis – Financial Results
Complete financial analysis of Purple Biotech Ltd. (PPBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Purple Biotech Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Meera Industries Limited (MEERA.BO) Income Statement Analysis – Financial Results
- Automatic Bank Services Limited (SHVA.TA) Income Statement Analysis – Financial Results
- Wakou Shokuhin Co., Ltd. (2813.T) Income Statement Analysis – Financial Results
- Accelerate Acquisition Corp. (AAQC-WT) Income Statement Analysis – Financial Results
- Uranium Energy Corp. (0LJQ.L) Income Statement Analysis – Financial Results
Purple Biotech Ltd. (PPBT)
About Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | -910.00K | -320.00K | 1.00M | 1.00M | 1.00M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 196.00K | 201.00K | 231.00K | 235.00K | 80.00 | 0.00 | 4.00K | 2.00K | 999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -196.00K | -1.11M | -551.00K | 765.00K | 999.92K | 1.00M | 897.00K | -2.00K | -999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 122.09% | 172.19% | 76.50% | 99.99% | 100.00% | 99.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.03M | 16.32M | 11.83M | 7.49M | 2.67M | 5.27M | 4.64M | 4.18M | 2.56M | 3.19M | 109.00K | 94.00 |
| General & Administrative | 0.00 | 5.96M | 5.82M | 6.07M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Selling & Marketing | 0.00 | 321.00K | 286.00K | 235.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.04M | 6.28M | 6.11M | 6.31M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Other Expenses | -44.54M | 0.00 | 0.00 | -15.66M | -216.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -22.47M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Cost & Expenses | -22.27M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Interest Income | 474.00K | 969.00K | 320.00K | 254.00K | 151.00K | 93.00K | 106.00K | 138.00K | 94.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.18M | 126.00K | 212.00K | 61.00K | 181.00K | 576.00K | 26.00K | 6.00K | 3.00K | 21.00K | 48.00K | 0.00 |
| Depreciation & Amortization | 199.00K | 201.00K | 231.00K | 235.00K | 178.00K | 7.00K | 4.00K | 2.00K | 1.00K | -50.00K | -27.00K | 957.22 |
| EBITDA | -22.23M | -21.49M | -17.52M | -28.41M | -6.14M | -5.55M | -12.88M | -7.04M | -4.20M | -5.43M | -2.58M | 255.22 |
| EBITDA Ratio | 0.00% | 2,355.27% | 5,432.19% | -2,796.00% | -763.80% | -772.60% | -1,323.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 22.27M | -22.60M | -17.93M | 12.61M | -7.16M | -7.83M | -12.25M | -7.18M | -4.07M | -5.18M | -2.55M | -702.00 |
| Operating Income Ratio | 0.00% | 2,483.85% | 5,604.38% | 1,261.20% | -715.60% | -782.60% | -1,359.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -42.25M | -43.52M | 108.00K | -15.46M | 1.48M | 2.26M | -947.00K | -4.94M | -133.00K | -71.00K | -75.00K | -1.00 |
| Income Before Tax | -19.98M | -21.76M | -17.83M | -28.07M | -5.89M | -5.57M | -13.01M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Income Before Tax Ratio | 0.00% | 2,391.21% | 5,570.63% | -2,807.40% | -589.30% | -556.90% | -1,443.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -935.00K | 637.00K | -15.67M | 216.00K | -2.63M | 26.00K | 4.94M | 133.00K | 50.00K | 27.00K | 0.00 |
| Net Income | -19.88M | -20.83M | -18.46M | -12.41M | -6.11M | -5.20M | -12.27M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Net Income Ratio | 0.00% | 2,288.46% | 5,769.69% | -1,240.50% | -610.90% | -520.00% | -1,362.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.49 |
| EPS Diluted | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.41 |
| Weighted Avg Shares Out | 221.33M | 18.48M | 17.80M | 17.21M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.00 |
| Weighted Avg Shares Out (Dil) | 221.33M | 18.48M | 17.80M | 17.21M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.55 |
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced...
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a...
Why Is Purple Biotech Stock Trading Higher On Monday?
On Monday, Purple Biotech Ltd PPBT reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC).
Purple Biotech Reports Third Quarter 2024 Financial Results
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific...
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 demonstrates s ustained tumor regression in a triple negative breast cancer in-vivo model ; A dose dependent ac tivity and a synergistic effect of the engage r arm s also seen in non-small cell lung cancer patient-derived explants
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
REHOVOT, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today reported new positive biomarker findings for its...
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced its executive management will participate...
Source: https://incomestatements.info
Category: Stock Reports